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ScienceDirectIf a freshly minted genome contains a mutation that confers drug
resistance, will it be selected in the presence of the drug? Not
necessarily. During viral infections, newly synthesized viral
genomes occupy the same cells as parent and other progeny
genomes. If the antiviral target is chosen so that the drug-
resistant progeny’s growth is dominantly inhibited by the drug-
susceptible members of its intracellular family, its outgrowth can
be suppressed. Precedent for ‘dominant drug targeting’ as a
deliberate approach to suppress the outgrowth of inhibitor-
resistant viruses has been established for envelope variants of
vesicular stomatitis virus and for capsid variants of poliovirus and
dengue virus. Small molecules that stabilize oligomeric
assemblages are a promising means to an unfit family to destroy
the effectiveness of a newborn drug-resistant relative due to the
co-assembly of drug-susceptible and drug-resistant monomers.
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Introduction
Darwinian theory postulates two requirements for evolu-
tion to occur. First, populations of individuals must display
pre-existing genetic diversity. Then, there must be suffi-
cient selection on survival or reproduction that some
members of the population and their progeny become
increasingly represented. Viruses often evolve quickly
due to the large population sizes, high mutation rates,
and rapidly changing environments. Dreaded evolutionary
events such as adaptation to new hosts or outgrowths ofCurrent Opinion in Virology 2016, 20:106–111 drug-resistant viruses continue to limit human ability to
control viral disease.
Mutational origins of viral diversity in intracellular RNA
viral genomes
The low-fidelity polymerases that copy the genomes of
RNA viruses are major contributors to viral diversity.
Figure 1a describes the infectious cycle and known
mutation frequencies of positive-strand viruses, but the
arguments are similar for negative-strand and double-
strand RNA viruses. The intrinsic misincorporation fre-
quencies of purified RNA-dependent RNA polymerases
during one templating event have been measured to be
3  105 misincorporations/nt for the NS5 polymerase of
dengue virus and 5  105 misincorporations/nt for puri-
fied 3D polymerases of foot-and-mouth-disease virus and
poliovirus [1]. The cumulative mutation frequency after a
single infectious cycle within a cell should then be this
intrinsic mutation frequency multiplied by the number of
templating events [reviewed in [2]].
Once the infecting RNAs are translated, the first intra-
cellular templating event is to copy an original positive
strand to a negative strand (Figure 1a). Then, further
positive-strand synthesis is templated from the negative
strand. In an extreme case, a ‘stamping model’, in which
all subsequent positive strands are templated by the
original negative strand, the error frequency per cell will
be 1  104 mutations/nt, or twice the intrinsic misincor-
poration frequency. More realistic schemes posit more
extended family trees, in which generations of negative
and positive strands template each other and the mutation
frequency per cell increases linearly with each intracellu-
lar generation. Using a clever circulization scheme
that minimizes artifactually introduced error, Acevado
et al. [3] found the cumulative error frequency of polio-
virus RNA replication to be 3  104 mutations/nt. This
predicts an average of three cycles of negative-strand and
positive-strand synthesis during one intracellular infec-
tious cycle. Note that an intracellular quasispecies is gener-
ated by the infectious cycles of RNA viruses, creating the
possibility that generations of RNA genomes that vary
slightly in sequence are in close contact. It is from this
intracellular viral diversity that newly synthesized drug-
resistant genomes are initially selected.
Approaches to suppressing drug resistance
The diversity of RNA viruses results from these high
mutation frequencies and other genetic events such aswww.sciencedirect.com
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Polyploid genetics of RNA viral infections. (a) The amplification scheme of a positive-strand RNA virus illustrates the principle of cumulative
error frequency, relevant to negative-stranded, double-stranded, and ambisense RNA genomes as well. (b) When mutations occur, the intracellular
accumulation of all parental and progeny genomes leads to the possibility of mixed oligomer formation, as exemplified by a chimeric poliovirus
capsid in which the gray subunits are bound to capsid inhibitor V-073 [10].deletion, recombination, reassortment, transduction of
cellular sequences, and the action of cellular editing
enzymers. There are two general strategies to thwart
the evolution of drug-resistant viruses: by reducing the
frequency of drug-resistant viruses or reducing the selection
for their outgrowth.
Reducing the frequency of drug-resistant viruses
Arguably the most successful strategy for the treatment of
highly mutable viruses is combination therapy: simulta-
neous treatment with multiple antivirals. The frequency
of variant viruses that are resistant to two or three drugs is
the multiple of the frequencies of each drug-resistant
variant to each individual drug. HIV-infected and HCV-
infected individuals are currently treated with combina-
tions of two to four medications that inhibit viral protein
functions or stimulate host responses. These combination
therapies are the result of decades of research by hun-
dreds of laboratories.
A second approach to reducing the frequency of drug-
resistant viruses is targeting host molecules required for viral
infections. If an antiviral targets a human protein, for
example, it is unlikely that genetic adaptation of host cells
to facilitate viral replication would be selected. Sometimes,
however, viruses escape drug inhibition by losing their
requirement for the targeted host function. For example,
HCV growth is dependent on cyclophilins, human proteins
whose proline isomerase activities are inhibited by
cyclosporin and related compounds. Nonetheless, drug-
resistant viral mutations can be selected [4–6]. However,
there are many host functions subverted and exploited by
viruses and targeting them is a promising approach.www.sciencedirect.com Reducing the selection of drug-resistant viruses
If an antiviral compound is targeted to a crucial point in an
enzyme or complex, it has been argued that drug-resistant
viruses will sometimes sustain a high fitness cost, becoming
so enfeebled by the mutation at these critical residues that
they are not selected even in the presence of drug. For
example, very low fitness was observed for the few HCV
variants isolated from patients who were treated with
polymerase inhibitor Sofosbuvir [7]. Nonetheless, high-
fitness viruses selected merely for growth were found to be
less susceptible to inhibition by Sofosbuvir [8]. Thus, the
phenomenon of fitness cost is difficult to predict.
An alternative approach, dominant drug targeting, seeks to
identify drug targets for which the inevitable drug-resis-
tant mutations arise but are not selected from the intra-
cellular quasispecies. Normally, for a drug target such as a
monomeric viral enzyme (Figure 2a), drug resistance is
dominant. Resistant genomes will encode resistant
enzymes that allow the infectious cycle to proceed for
the genome that encodes them. In some cases, resistant
products can also provide helper functions that also allow
the escape of drug-susceptible viruses and, it is very
likely, provide helper functions that allow the escape
of drug-susceptible viruses as well.
Many RNA viral products, however, form trans-assem-
bling oligomers such as capsid and matrix constituents
and ribonucleoprotein complexes. For oligomeric drug
targets as well as monomeric ones, drug-resistant muta-
tions pre-exist in every viral stock and can be selected in
tissue culture through passage at low multiplicities of
infection (MOIs). However, when a drug-resistant muta-
tion first occurs in an infected cell, it is not alone, but inCurrent Opinion in Virology 2016, 20:106–111
108 Engineering for viral resistance
Figure 2
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The selection pressures on drug-resistant viruses differ with target biochemistry. (a) When antiviral targets are trans-acting monomeric
proteins or cis-acting molecules [31], production of drug-resistant entities directly benefits replication of the drug-resistant genome. Thus,
selection for drug resistance is unimpeded. (b) When the drug target is a trans-assembling oligomer, the formation of chimeric oligomers can lead
to suppression of the drug-resistant phenotype.the presence of many drug-susceptible genomes
(Figure 2b). Then, if the protein subunits assemble in
trans, oligomers that contain drug-resistant subunits will
also contain drug-susceptible ones. If the ratio of suscep-
tible:resistant subunits is high enough, these chimeric
structures will be nonfunctional in the presence of the
drug and thus drug susceptibility will be genetically dominant.
Effectiveness of dominant drug targeting
The most intuitive examples of a highly oligomeric, trans-
assembling assemblage during viral infections are struc-
tural proteins such as cores and capsids. The ability of unfit
viruses to suppress the growth of more fit viruses present
in the same cell was documented for the major surface
glycoprotein (G-protein) of vesicular stomatitis virus by
the laboratory of Esteban Domingo [9]. Vesicular stoma-
titis virus variants resistant to neutralization by monoclo-
nal antibodies could be readily recovered by passage in
cultured cells at low MOIs. However, when virus was
passaged at MOIs of 5 PFU/cell or higher, the recovery of
neutralization-resistant variants were suppressed 400-fold.
The authors hypothesized that the mixing of G-proteins
within cells (1B) led to the ‘phenotypic masking’ of
antibody-resistant mutations and prevented their selec-
tion. The concept of phenotypic masking is, in more
conventional terms, the genetic dominance of the anti-
body-sensitive over the antibody-resistant phenotype.
Like the dominance of antibody-sensitive phenotypes, we
reasoned that some drug-susceptible phenotypes might be
dominant over newly arising genomes that could encoded
potentially drug-resistant phenotypes. To test this hypoth-Current Opinion in Virology 2016, 20:106–111 esis, the genetic relationships between drug-resistant and
drug-susceptible viruses for different drug targets was
determined in both poliovirus and dengue virus
[10,11,12]. For inhibitors that target the active sites of
viral enzymes such as poliovirus NTPase (Figure 3a) and
the dengue virus RNA-dependent RNA polymerase
(Figure 3c), drug-resistance viruses were dominant. How-
ever, for inhibitors of the poliovirus capsid (Figure 3b) or
dengue virus core proteins (Figure 3d), drug resistance was
suppressed when drug-susceptible viruses were present in
the same cell. The dominance of drug susceptibility in tissue
culture correlated with the suppression of drug resistance
during growth of these viruses in mouse models
(Figure 3e).
To identify other potential dominant drug targets besides
capsid proteins, we look to the literature of dominant-
negative mutations [13]. A recent contribution to the
endogenous retrovirus literature is a description of
Refrex-1, a truncated envelope protein encoded in the
genomes of domestic cats that confers protection from
feline leukemia virus infection by titration of the viral
receptor [14]. The genome of thirteen-lined ground
squirrels encodes a protein that is highly homologous
to bornavirus nucleoprotein; this host restriction factor
inhibits exogenous bornavirus infection by incorporating
into viral ribonucleoprotein complexes [15]. These
examples illustrate two of the mechanisms for molecular
dominance by defective proteins described by Hersko-
witz: competition for a limiting binding partner and
inactivation of oligomeric complexes by the formation
of chimeras [13].www.sciencedirect.com
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Figure 3
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Some antiviral targets allow the selection of drug-resistant variants and some do not. (a) At low concentrations, guanidine hydrochloride is a
potent inhibitor of picornavirus RNA replication, and resistant mutations map to viral NTPase 2C [32]. When cells were infected with a drug-
resistant variant in the presence of increasing amounts of drug-susceptible virus, drug resistance is dominant. (b) V-073 is a compound being
developed for the poliovirus eradication campaign [33] and has 60 binding sites on the poliovirus capsid (Fig. 1b). Drug-susceptibity is dominant.
(c) MK-0608 is a nucleoside analog that inhibits the active site of hepatitis C, dengue, and zika virus polymerases [34–36]. Drug resistance is
dominant. (d) ST-148 is a small molecule that hyper-stabilizes dengue core protein oligomers [37,38]. Drug susceptibility is dominant. (e) Poliovirus
and dengue virus were grown in susceptible mice for five and four days, respectively, in the presence of individual antiviral compounds. Reduced
selection for drug resistance was observed for the capsid and core inhibitors.Competition for limiting resources is likely to be the
mechanism by which defective interfering viral particles
inhibit the growth of the competent, wild-type genomes.
A strategy to deploy engineered defective interfering
particles of HIV to fight the infection is a promising and
daring idea [12,16]. On the other hand, defective chimera
formation is likely to be the mechanism for many domi-
nant-negative effects of defective viral products. Isolated
domains of alphavirus, flavivirus, and HIV structural
proteins can inhibit virus membrane fusion, presumably
by forming mixed oligomers [17–19], and uncleaved
precursors of HIV capsids dominantly inhibit viral
maturation by hyperstabilizing the highly oligomeric
immature capsid [20]. Expression of nonstructural
viral proteins can also dominantly inhibit intracellular
processes. Mutant influenza PB1 proteins and defective
HCV NS5A proteins have both been shown to dominant-
ly interfere with viral replication in cultured cells
[21,22].
We have used an approach of co-transfecting wild-type
and non-viable mutant RNAs to identify mutations that
dominantly inhibit the growth of wild-type poliovirus. Of
the several single polymerase mutations tested, only
those near the ‘translocation loop’ [23] were found to
have dominant negative effects. From these studies, we
conclude that promising dominant drug targets in RNA
viruses include capsids, cores, replicase functions in ini-
tiation and translocation and intramolecularly cleaving
proteases [24]. Other oligomers, such as the matrix
proteins of enveloped viruses and components ofwww.sciencedirect.com negative-strand ribonucleoprotein complexes are excel-
lent candidates as well.
Broadening the concept of dominant-drug
targeting
Drug-resistant viruses can be selected within an organism
at several stages. The initial inoculum, if sufficiently
large, can already include mutant genomes resistant to
any single antiviral compound. Assuming no previous
drug selection, such variants are expected to present at
frequencies no greater than 104 until subject to selec-
tion. When viruses are replicating intracellularly, drug-
resistant variants will arise within populations of relatives
that can help or hinder their growth and selection. This is
the stage at which the dominant drug targeting strategy
can exert a powerful effect. Any drug-resistant viruses
that escape their cell of origin may then have the oppor-
tunity to infect new cells in the absence of other family
members, which can readily lead to selection for drug
resistance. However, many viruses do not spread disper-
sively, but locally, to neighboring cells. In these cases, any
escaping drug-resistant virus is likely to co-infect these
neighboring cells with its susceptible cousins, thus con-
tinuing the dominant inhibitory effect.
How general is the principle of dominant drug targeting?
Some other events that give rise to drug resistance arise in
polyploid genetic environments. One usually thinks of
retroviruses, with their high error frequencies, of being in
this category, but retroviral diversity is predominantly
extracellular and thus not conducive to the dominant drugCurrent Opinion in Virology 2016, 20:106–111
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Figure 4
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Examples of intercellular and intracellular variation. (a) Retroviruses synthesize new genomes via cellular transcription, but the most error-
prone step is reverse transcription. (b) Many bacteria and eukaryotic parasites amplify within cells. Although products within the microbial cells are
not shared between organisms, many of the virulence factors that they encode are secreted into a common milieu, creating the possibility of
dominant inhibition of drug-resistant variants by drug-susceptible subunits. The oligomeric states of most of these virulence factors are not known.
(c) The proliferation of cancer cells is often driven by the amplification of oncogenes or growth factors. It is possible that drug resistance could be
thwarted should the drug target by an oligomeric product of such amplification events.targeting strategy. The most error-prone step in the retro-
virus infectious cycle is reverse transcription of the two
packaged strands of genomic RNA into double-stranded
DNA (Figure 4a). The misincorporation frequencies of
reverse transcriptases are high: recent measurements of
the misincorporation frequency of purified HIV reverse
transcriptase by deep sequencing have shown 104 mis-
misincorporations/nt [25]. Subsequent steps — the repli-
cation of integrated viral DNA, with the low host
misincorporation frequency [(1010/nt) [26]] and the
generation of new genomic RNA by host transcription
[(105–106/nt) [27]] — generate comparatively little in-
tracellular variability. If we assume that retroviral infec-
tions of individual cells are mostly initiated by single
virions, the genetic diversity will be predominantly between
infected cells rather than within single infected cells.
Intracellular bacteria and eukaryotic parasites that repli-
cate within human cells can, at the error frequency of
their DNA polymerases, generate variants that confer
resistance to anti-microbial compounds. Such pathogens
are known to secrete virulence factors into a shared mileiu
(Figure 4b) to hijack host machinery to support their
replication and evade innate immune responses. Any of
these factors that are oligomeric, such as anthrax toxin
[28] could be dominant drug targets.
The effectiveness of most cancer chemotherapies is
compromised by drug resistance [reviewed in [29]]. Gene
duplication events are common and can correlate with
aggressive tumorigenesis and drug resistance. Some
oncogenes thus amplified, such as HER2, function asCurrent Opinion in Virology 2016, 20:106–111 homodimers or heterodimers [30]. As is the case with
viruses, drugs that hyperstabilize homo-oligomers have
the potential to decrease selection for resistant mutations.
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